Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer
Lung cancer is the leading cause of cancer death worldwide. Despite the emergence of highly effective targeted therapies, up to 30% of advanced stage non-small cell lung cancer (NSCLC) patients do not undergo tissue molecular testing because of scarce tissue availability. Liquid biopsy, on the other...
Main Authors: | Pasquale Pisapia, Francesco Pepe, Antonino Iaccarino, Roberta Sgariglia, Mariantonia Nacchio, Gianluca Russo, Gianluca Gragnano, Elalah Mosaieby, Giancarlo Troncone, Umberto Malapelle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Journal of Molecular Pathology |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-5261/2/3/21 |
Similar Items
-
BRAF: A Two-Faced Janus
by: Pasquale Pisapia, et al.
Published: (2020-11-01) -
Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer
by: Pasquale Pisapia, et al.
Published: (2021-02-01) -
Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting
by: Umberto Malapelle, et al.
Published: (2021-07-01) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01) -
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)